Pentasa (Mesalamine) - Summary

PENTASA SUMMARY

PENTASA®
(mesalamine)
Controlled-Release Capsules 250 mg and 500 mg

PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an aminosalicylate anti-inflammatory agent for gastrointestinal use.

PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.

PENTASA NEWS HIGHLIGHTS

Media Articles Related to Pentasa (Mesalamine)

Mesalamine Granules Maintain Remission In Ulcerative Colitis Patients Who Switch From Another 5-ASA
Source: Clinical Trials / Drug Trials News From Medical News Today [2008.10.08]

ACG: Once-Daily Mesalamine Maintains Remission in Ulcerative Colitis
Source: MedPage Today Gastroenterology [2008.10.08]

Shire Announces Results From An Analysis Of LIALDA And Asacol For The Treatment Of UC
Source: Conferences News From Medical News Today [2008.10.07]

more>>

Published Studies Related to Pentasa (Mesalamine)

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. [2007.12]

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. [2007.01]

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [2005.11]

Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. [2005.07]

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. [2005.07]

more>>

Clinical Trials Related to Pentasa (Mesalamine)

A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease [Completed]

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I) [Completed]

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis [Completed]

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis [Terminated]

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis. [Completed]

more>>